ReviewClinical and molecular hepatology2022
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound.
Review in Clinical and molecular hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Hepatobiliary phase imaging in HCC: revisiting diagnostic algorithms and clinical utility of gadoxetic acid-enhanced MRI across international guidelines.Insights into imaging · 2026Review
- Non-invasive model for predicting future lung metastasis of hepatocellular carcinoma based on imaging heterogeneity analysis.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Prognostic Value ofCancers · 2026Article
- Integrated multi-task learning framework for hepatocellular carcinoma segmentation and histological grading using fused multi-phase MRI.Abdominal radiology (New York) · 2026Article
- The Current Research Landscape on Integrating Artificial Intelligence with Ultrasound Imaging for Cancer Diagnosis: A Dual-Database Bibliometric Study.Current medicinal chemistry · 2026Article
- The diagnostic accuracy of imaging methods in preoperative prediction of vessels encapsulating tumor clusters in hepatocellular carcinoma in East Asian populations: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2026Article
- Dynamic contrast-enhanced ultrasound perfusion analysis for preoperative prediction of aggressive hepatocellular carcinoma subtypes.Insights into imaging · 2025Article
- Comparative evaluation of non-contrast MRI versus gadoxetic acid-enhanced abbreviated protocols in detecting colorectal liver metastases.Insights into imaging · 2025Article
- Radiomics and Deep Learning as Important Techniques of Artificial Intelligence - Diagnosing Perspectives in Cytokeratin 19 Positive Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Review
- Re-assessing the diagnostic value of the enhancing capsule in hepatocellular carcinoma imaging.Journal of liver cancer · 2024Article
- Article
- Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.European radiology · 2024Article
- Sonazoid-enhanced ultrasonography for noninvasive imaging diagnosis of hepatocellular carcinoma: special emphasis on the 2022 KLCA-NCC guideline.Ultrasonography (Seoul, Korea) · 2023Article
- Sonazoid contrast-enhanced ultrasonography for the diagnosis of hepatocellular carcinoma: strengths and shortcomings.Journal of liver cancer · 2023Article
- Development of a deep-learning model for classification of LI-RADS major features by using subtraction images of MRI: a preliminary study.Abdominal radiology (New York) · 2023Article
- Compared with CT/MRI LI-RADS, whether CEUS LI-RADS is worth popularizing in diagnosis of hepatocellular carcinoma?-a direct head-to-head meta-analysis.Quantitative imaging in medicine and surgery · 2023Article
- Article
- Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective.Clinical and molecular hepatology · 2023Review
- Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.Clinical and molecular hepatology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a unique cancer entity that can be noninvasively diagnosed using imaging modalities without pathologic confirmation. In 2018, several major guidelines for HCC were updated to include hepatobiliary contrast agent magnetic resonance imaging (HBA-MRI) and contrast-enhanced ultrasound (CEUS) as major imaging modalities for HCC diagnosis. HBA-MRI enables the achievement of high sensitivity in HCC detection using the hepatobiliary phase (HBP). CEUS is another imaging modality with real-time imaging capability, and it is reported to be useful as a second-line modality to increase sensitivity without losing specificity for HCC diagnosis. However, until now, there is an unsolved discrepancy among guidelines on whether to accept "HBP hypointensity" as a definite diagnostic criterion for HCC or include CEUS in the diagnostic algorithm for HCC diagnosis. Furthermore, there is variability in terminology and inconsistencies in the definition of imaging findings among guidelines; therefore, there is an unmet need for the development of a standardized lexicon. In this article, we review the performance and limitations of HBA-MRI and CEUS after guideline updates in 2018 and briefly introduce some future aspects of imaging-based HCC diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.